TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Placebo-Controlled Trial of N-acetylcysteine for the Treatment of Pediatric Trichotillomania
Brief Summary: Trichotillomania (hair pulling) has an estimated lifetime prevalence of 1-3%. Children with trichotillomania can experience significant impairment due to peer teasing, avoidance of activities (such as swimming and socializing), difficulty concentrating on school work and medical complications due to pulling behaviors. Despite the fact that trichotillomania has a childhood onset, no randomized, controlled trials have been completed in childhood trichotillomania.

Research in adults with trichotillomania has demonstrated that most commonly currently prescribed treatment for trichotillomania, (pharmacotherapy with selective serotonin reuptake inhibitors) is ineffective in treating this condition. By contrast, randomized controlled trials in adults have suggested the efficacy of N-acetylcysteine as well as behavioral treatments such as Habit Reversal Therapy.

The goal of this trial is to determine the efficacy of N-Acetylcysteine for pediatric trichotillomania. N-Acetylcysteine is a glutamate modulating agent, with a fairly benign side-effect profile.


Options:
A: Arm Label: Dronabinol; Type: EXPERIMENTAL; Interventions: Drug: Dronabinol | Intervention Type: DRUG; Name: Dronabinol; Assigned to Arm(s): Dronabinol
B: Arm Label: N-Acetyl Cysteine; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-Acetyl Cysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: N-Acetyl Cysteine; Assigned to Arm(s): N-Acetyl Cysteine
C: Arm Label: N-acetylcysteine (NAC); Type: EXPERIMENTAL; Interventions: Drug: N-Acetylcysteine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N-acetylcysteine (NAC) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naltrexone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized Trial of Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas
Brief Summary: Previous studies addressing preoperative somatostatin analogs (SSA) treatment and subsequent surgical cure rates are conflicting, reporting a benefit, or no difference between groups. And most reported studies were rather small and were made in retrospect, we conducted a prospective, randomized study to investigate whether 4-month preoperative lanreotide treatment would improve the surgical cure rate of newly diagnosed acromegalic patients with macroadenomas. The investigators also aimed to investigate whether there were differences in the incidence of surgical complications, and duration of neurosurgical hospital stay.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide Implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sandostatin LAR Depot | Intervention Type: DRUG; Name: Octreotide Implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sandostatin LAR Depot; Assigned to Arm(s): 2
B: Arm Label: Group 2; Type: OTHER; Interventions: Procedure: Transsphenoidal surgery | Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Preoperative lanreotide treatment | Intervention Type: DRUG; Name: Preoperative lanreotide treatment; Assigned to Arm(s): Group 1 | Intervention Type: PROCEDURE; Name: Transsphenoidal surgery; Assigned to Arm(s): Group 2
C: Arm Label: octreotide; Type: EXPERIMENTAL; Interventions: Drug: Octreotide | Arm Label: standard surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Direct surgery for acromegaly | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): octreotide | Intervention Type: PROCEDURE; Name: Direct surgery for acromegaly; Assigned to Arm(s): standard surgery
D: Arm Label: CAM2029 10 mg (NET); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 20 mg (NET); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 10 mg (Acromegaly); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 20 mg (Acromegaly); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Intervention Type: DRUG; Name: octreotide FluidCrystal® injection depot; Assigned to Arm(s): CAM2029 10 mg (Acromegaly), CAM2029 10 mg (NET), CAM2029 20 mg (Acromegaly), CAM2029 20 mg (NET)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Multinational, Open-label, Single-dose Acute Hemodynamic Study Followed by Multi-centre, Multinational, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy (Proof-of-concept) of ACT-293987 (NS-304) in the Treatment of Pulmonary Arterial Hypertension in Subjects Aged 18 Years and Over
Brief Summary: This is a multi-centre, multinational, open-label, single-dose acute hemodynamic study followed by randomized, double-blind, parallel-group, placebo controlled study. Eligible subjects will undergo an open-label, single-dose acute hemodynamic study with ACT-293987(NS-304) and 21 weeks of double-blind treatment during which subjects will receive either ACT-293987 (NS-304) or placebo b.i.d. Subjects who have completed the double-blind study can enter the open extension study (separate protocol) and receive administration of ACT-293987 (NS-304) if the subject wishes and the Investigator considers it appropriate.


Options:
A: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral treprostinil (UT-15C) sustained release tablets | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral treprostinil (UT-15C) sustained release tablets; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
B: Intervention Type: DRUG; Name: Remodulin (treprostinil sodium); Assigned to Arm(s): N/A
C: Arm Label: ACT-293987 (NS-304) and matching placebo; Type: EXPERIMENTAL; Interventions: Device: ACT-293987 (NS-304) | Intervention Type: DEVICE; Name: ACT-293987 (NS-304); Assigned to Arm(s): ACT-293987 (NS-304) and matching placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: UT-15C SR; Type: EXPERIMENTAL; Interventions: Drug: UT-15C SR | Intervention Type: DRUG; Name: UT-15C SR; Assigned to Arm(s): UT-15C SR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: INTRAVITREAL RANIBIZUMAB FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (INIPE STUDY)
Brief Summary: To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic retinopathy.


Options:
A: Arm Label: Intravitreal anti-VEGF; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal injection of ranibizumab | Intervention Type: DRUG; Name: Intravitreal injection of ranibizumab; Assigned to Arm(s): Intravitreal anti-VEGF
B: Arm Label: Avastin Injection Group (AIG); Type: EXPERIMENTAL; Interventions: Drug: Avastin (bevacizumab) | Arm Label: Sham Injection Group (SIG); Type: SHAM_COMPARATOR; Interventions: Other: Sham injection | Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): Avastin Injection Group (AIG) | Intervention Type: OTHER; Name: Sham injection; Assigned to Arm(s): Sham Injection Group (SIG)
C: Arm Label: Panretinal Photocoagulation (PRP); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Panretinal Photocoagulation (PRP) | Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Intravitreous injection of ranibizumab | Arm Label: Ranibizumab + Panretinal Photocoagulation (PRP); Type: EXPERIMENTAL; Interventions: Procedure: Panretinal Photocoagulation (PRP), Drug: Intravitreous injection of ranibizumab | Intervention Type: PROCEDURE; Name: Panretinal Photocoagulation (PRP); Assigned to Arm(s): Panretinal Photocoagulation (PRP), Ranibizumab + Panretinal Photocoagulation (PRP) | Intervention Type: DRUG; Name: Intravitreous injection of ranibizumab; Assigned to Arm(s): Ranibizumab, Ranibizumab + Panretinal Photocoagulation (PRP)
D: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: INTRAVITREAL RANIBIZUMAB FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (INIPE STUDY)
Brief Summary: To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic retinopathy.


Options:
A: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg
B: Arm Label: Avastin Injection Group (AIG); Type: EXPERIMENTAL; Interventions: Drug: Avastin (bevacizumab) | Arm Label: Sham Injection Group (SIG); Type: SHAM_COMPARATOR; Interventions: Other: Sham injection | Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): Avastin Injection Group (AIG) | Intervention Type: OTHER; Name: Sham injection; Assigned to Arm(s): Sham Injection Group (SIG)
C: Arm Label: Intravitreal anti-VEGF; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal injection of ranibizumab | Intervention Type: DRUG; Name: Intravitreal injection of ranibizumab; Assigned to Arm(s): Intravitreal anti-VEGF
D: Arm Label: Saline Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline Injection

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Randomized, Single-blind, Placebo-controlled, Multicenter Study to Evaluate the Immunogenicity of Pneumococcal and Influenza Vaccines in Adult Subjects With Rheumatoid Arthritis Receiving Certolizumab Pegol or Placebo
Brief Summary: The purpose of this trial is to assess the affect of Certolizumab Pegol (CZP) treatment on antibody response to T cell-independent and T cell-dependent immunizations using pneumococcal and influenza vaccines, respectively.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cimzia; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Cimzia
B: Arm Label: RAPID3 to assess response to Cimzia; Type: OTHER; Interventions: Biological: Certolizumab Pegol (CZP) | Arm Label: CDAI to assess response to Cimzia; Type: OTHER; Interventions: Biological: Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP); Assigned to Arm(s): CDAI to assess response to Cimzia, RAPID3 to assess response to Cimzia
C: Arm Label: Certolizumab pegol (CZP); Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol (CZP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol (CZP); Assigned to Arm(s): Certolizumab pegol (CZP) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phae 2 Efficacy Trial of AV Lotion for the Prevention of Cold Illness in Human Subjects
Brief Summary: The purpose of this of this study is to determine if 3804-250A can prevent the common cold caused by the rhinovirus when applied to the hands. The study will also evaluate whether 3804-250A can prevent rhinovirus infection or common cold illnesses.

The study will also evaluate the safety of 3804-250A.


Options:
A: Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3804-250A lotion; Type: EXPERIMENTAL; Interventions: Drug: 3804-250A | Intervention Type: DRUG; Name: 3804-250A; Assigned to Arm(s): 3804-250A lotion
B: Arm Label: 1; Type: OTHER; Interventions: Other: Control | Arm Label: 2; Type: OTHER; Interventions: Device: Masks | Arm Label: 3; Type: OTHER; Interventions: Device: Masks & hand hygiene | Intervention Type: DEVICE; Name: Masks; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Masks & hand hygiene; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): 1
C: Arm Label: Vitamin D and gargling; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3), Behavioral: Gargling | Arm Label: Vitamin D and general health advice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3) | Arm Label: Placebo and general health advice; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Placebo and gargling; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Gargling, Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): Vitamin D and gargling, Vitamin D and general health advice | Intervention Type: BEHAVIORAL; Name: Gargling; Assigned to Arm(s): Placebo and gargling, Vitamin D and gargling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo and gargling, Placebo and general health advice
D: Arm Label: Vaccine arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: ShanChol | Arm Label: Vaccine plus hygiene and safe water arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Vaccine and behaviour | Arm Label: Non-intervention arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: ShanChol; Assigned to Arm(s): Vaccine arm | Intervention Type: BEHAVIORAL; Name: Vaccine and behaviour; Assigned to Arm(s): Vaccine plus hygiene and safe water arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phae 2 Efficacy Trial of AV Lotion for the Prevention of Cold Illness in Human Subjects
Brief Summary: The purpose of this of this study is to determine if 3804-250A can prevent the common cold caused by the rhinovirus when applied to the hands. The study will also evaluate whether 3804-250A can prevent rhinovirus infection or common cold illnesses.

The study will also evaluate the safety of 3804-250A.


Options:
A: Arm Label: Hand washing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hand washing | Arm Label: Disinfectant rubbing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Disinfectant rubbing | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Hand washing; Assigned to Arm(s): Hand washing | Intervention Type: BEHAVIORAL; Name: Disinfectant rubbing; Assigned to Arm(s): Disinfectant rubbing
B: Arm Label: Facemask and hand hygiene; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask, Behavioral: 62% Ethyl Alcohol Hand Sanitizer | Arm Label: Facemask only; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Ear Loop Procedure Mask; Assigned to Arm(s): Facemask and hand hygiene, Facemask only | Intervention Type: BEHAVIORAL; Name: 62% Ethyl Alcohol Hand Sanitizer; Assigned to Arm(s): Facemask and hand hygiene
C: Arm Label: N95 Respirator; Type: ACTIVE_COMPARATOR; Interventions: Device: N95 Respirator | Arm Label: Medical/surgical mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Medical/surgical mask | Intervention Type: DEVICE; Name: N95 Respirator; Assigned to Arm(s): N95 Respirator | Intervention Type: DEVICE; Name: Medical/surgical mask; Assigned to Arm(s): Medical/surgical mask
D: Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3804-250A lotion; Type: EXPERIMENTAL; Interventions: Drug: 3804-250A | Intervention Type: DRUG; Name: 3804-250A; Assigned to Arm(s): 3804-250A lotion

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phae 2 Efficacy Trial of AV Lotion for the Prevention of Cold Illness in Human Subjects
Brief Summary: The purpose of this of this study is to determine if 3804-250A can prevent the common cold caused by the rhinovirus when applied to the hands. The study will also evaluate whether 3804-250A can prevent rhinovirus infection or common cold illnesses.

The study will also evaluate the safety of 3804-250A.


Options:
A: Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3804-250A lotion; Type: EXPERIMENTAL; Interventions: Drug: 3804-250A | Intervention Type: DRUG; Name: 3804-250A; Assigned to Arm(s): 3804-250A lotion
B: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Escola L'Horitzó | Arm Label: Control Group; Type: OTHER; Interventions: Other: Escola John Talabot | Intervention Type: OTHER; Name: Escola L'Horitzó; Assigned to Arm(s): Experimental group | Intervention Type: OTHER; Name: Escola John Talabot; Assigned to Arm(s): Control Group
C: Arm Label: Group 1- The saliva ejector; Type: ACTIVE_COMPARATOR; Interventions: Device: The saliva ejector | Arm Label: Group 2- The high-volume evacuator; Type: ACTIVE_COMPARATOR; Interventions: Device: The high-volume evacuator | Arm Label: Group 3- The DryShield; Type: ACTIVE_COMPARATOR; Interventions: Device: The DryShield | Intervention Type: DEVICE; Name: The saliva ejector; Assigned to Arm(s): Group 1- The saliva ejector | Intervention Type: DEVICE; Name: The high-volume evacuator; Assigned to Arm(s): Group 2- The high-volume evacuator | Intervention Type: DEVICE; Name: The DryShield; Assigned to Arm(s): Group 3- The DryShield
D: Arm Label: N95 Respirator; Type: ACTIVE_COMPARATOR; Interventions: Device: N95 Respirator | Arm Label: Medical/surgical mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Medical/surgical mask | Intervention Type: DEVICE; Name: N95 Respirator; Assigned to Arm(s): N95 Respirator | Intervention Type: DEVICE; Name: Medical/surgical mask; Assigned to Arm(s): Medical/surgical mask

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phae 2 Efficacy Trial of AV Lotion for the Prevention of Cold Illness in Human Subjects
Brief Summary: The purpose of this of this study is to determine if 3804-250A can prevent the common cold caused by the rhinovirus when applied to the hands. The study will also evaluate whether 3804-250A can prevent rhinovirus infection or common cold illnesses.

The study will also evaluate the safety of 3804-250A.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Alcohol-based hand sanitizer & quaternary ammonium wipes | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Alcohol-based hand sanitizer & quaternary ammonium wipes; Assigned to Arm(s): 1
B: Arm Label: Water quality; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Water quality | Arm Label: Sanitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Sanitation | Arm Label: Hand washing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hand washing | Arm Label: Combined WASH; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Water quality, Sanitation, Hand washing (Combined WASH) | Arm Label: Nutrition; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nutrition | Arm Label: Nutrition + Combined WASH; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nutrition, Water quality, Sanitation, Hand washing | Arm Label: Non-intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Water quality; Assigned to Arm(s): Water quality | Intervention Type: BEHAVIORAL; Name: Sanitation; Assigned to Arm(s): Sanitation | Intervention Type: BEHAVIORAL; Name: Hand washing; Assigned to Arm(s): Hand washing | Intervention Type: BEHAVIORAL; Name: Water quality, Sanitation, Hand washing (Combined WASH); Assigned to Arm(s): Combined WASH | Intervention Type: BEHAVIORAL; Name: Nutrition; Assigned to Arm(s): Nutrition | Intervention Type: BEHAVIORAL; Name: Nutrition, Water quality, Sanitation, Hand washing; Assigned to Arm(s): Nutrition + Combined WASH
C: Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3804-250A lotion; Type: EXPERIMENTAL; Interventions: Drug: 3804-250A | Intervention Type: DRUG; Name: 3804-250A; Assigned to Arm(s): 3804-250A lotion
D: Arm Label: Hand sanitizer group; Type: EXPERIMENTAL; Interventions: Other: hand sanitizer | Arm Label: Liquid soap group; Type: EXPERIMENTAL; Interventions: Other: liquid soap | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: hand sanitizer; Assigned to Arm(s): Hand sanitizer group | Intervention Type: OTHER; Name: liquid soap; Assigned to Arm(s): Liquid soap group

Answer: C